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Introduction
It has been only since early 1980’s, that 
medical research began to actively consider 
gender issues.1 Gender differences have, 
in fact, been identified in the initiation 
of medicines, escalation of use, addiction 
and relapse following abstinence for drug 
abuse.2 Gender differences have also been 
found in terms of disease prevention, clinical 
signs of disease, therapeutic approach, 
and prognosis, psychological and social 
impact.3  For example, overall rates of 
medicine consumption have been found 
to be significantly higher in males than in 
females.4 
Such differences could be due to 
physiological differences between sexes, 
which affect the pharmacokinetics 
and the pharmacodynamics of drugs.  
Pharmacokinetics involves the rate and 
extent of drug movement through the 
body, including absorption, distribution, 
metabolism, and excretion. Females have a 
tendency for lower body weights and slower 
gastrointestinal tract movements, which 
indicates a need to prolong time intervals, 
between meals and medication.5 
Several physiologic differences between 
men and women may account for variations 
in pharmacokinetics, which can affect 
the dosages of medications with narrow 
therapeutic indices.5  For example, drug 
clearance tends to be slower in women, and 
medications with a narrow therapeutic index 
and a higher potential for toxicity, such as 
digoxin, need to have their dose titrated for 
the specific patient.6
Pharmacodynamics is the study of 
drug mechanism of action, including the 
physiologic and biochemical effects on the 
body, and the relationship between drug 
concentration and the rate and extent of 
pharmacologic response.6 Therefore, in any 
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given blood concentration, a drug may 
invoke variations in response, including 
differences in effectiveness or safety.6 
Some differences in medication effects 
between men and women, and subsequent 
recommendations are listed in Table 1.
Women are 50 to 75 percent more likely 
than men to experience an adverse drug 
reaction.7 These differences may be caused 
by increased polypharmacy, increased drug 
bioavailability, and greater sensitivity to 
medication.8 
Access to medicines in Malta
Malta does not have a reimbursement system. 
Patients are entitled to receive free medicines 
depending on a number of set criteria. Access 
to free medicines under NHS is regulated by 
Schedule V scheme which lists the chronic 
medical conditions for which patients in 
Malta are entitled to free medicines. 9
In 2012, legislative changes were made 
to the Social Security Act Cap 318 Article 
23 and the Fifth Schedule of the same Act 
resulting in an increase in the number of 
listed Schedule V medical conditions, from 
38 to 79. 9 In 2014 two further conditions, 
fibromyalgia and encephalomyelitis were 
added to this list. Patients suffering from 
a chronic medical condition which is listed 
under the second part of the Fifth Schedule 
of the Social Security Act are entitled to 
free medication for that specific disease 
and entitlement is based solely upon the 
presence of disease irrespective of means, 
income or age. 9 
Additionally patients with limited means 
are generally entitled to the Schedule 
II (Pink Card).  Pink card holders are entitled 
to a limited number of medicinal products.9
Moreover, some medicines available 
under NHS are regulated with an additional 
protocol and the necessary approvals are 
made on an interim basis for the necessary 
follow-up to take place.  These medicines are 
usually regulated due to the costs.9
In Malta there is no national drug 
consumption data. Information is highly 
fragmented and not collected in a manner 
conducive to determine drug consumption. 
A limited number of protocol regulated 
medicines will be presented in this paper. 
This however is far from the actual picture
Consumption of medicine data through free 
entitlement
In this paper, disaggregated gender data 
for the consumption of medicine through 
free entitlement in Malta, is described. Data 
was provided by the Central Procurement 
Supplies Unit (CPSU)10 and the Medicines 
Entitlement databases (Schedule V and 
protocol-regulated databases). In Malta, 
CPSU is responsible for the management 
of all procurement processes related to 
the supplies, services and works across the 
Ministry for Health in line with Government 
Public Procurement Regulations.11 Analysis 
of such data theoretically should provide the 
possibility of extrapolating information about 
possible differences between genders in use 
of medicines indicated for some conditions. 
In calendar year 2013, approximately, 
seventy eight Million Euros were spent on 
medicines and medical materials/surgical 
devices in Malta.  This data retrieved from 
the CPSU10, provides information on the 
medicines, borderline substances listed on 
the published Government Formulary List and 
on other items procured.  The Government 
Formulary List12 includes approximately 1300 
introduced items.  There are also medicines 
which are not listed and which are procured 
through the Exceptional Medicines Treatment 
Policy to target urgent clinical cases or 
gaps within the Government Formulary, 
until there is the formal introduction 
for this medicine in the formulary, as 
regulated by through Legal notice LN 
58/2009.13. The equipment and, medical/
surgical devices are not included in the 
government formulary list.12   
Gender differences in protocol regulated 
anti-asthmatic drug consumption in Malta
Asthma is usually treated with drugs 
which reduce inflammation and provide 
bronchodilation.14  Prevalence of asthma 
is higher in males than in females before 
adolescence, however the trend changes 
after puberty.15  The higher prevalence of 
asthma in boys has been proposed to be 
due to the airways in males developing 
more slowly, as compared to lung volume 
and thus males are more prone to indoor 
allergens.16   Various asthma studies have 
in fact shown differences in anti-asthmatic 
drug use due to gender and age.17  Some 
studies also indicate that responses to anti-
asthmatic drugs differ between sexes.15 
In Malta, in March 2014, the data 
from CPSU and the protocol-regulated 
entitlement database indicated that there 
were 254 (67.7%) female patients on 
budesonide inhalers,with 8 patients under 
16 years.  On the other hand, there were 
121 (32.3%) males on these inhalers, with 
4 patients being under 16 years old.  The 
other inhaled steroids are not included 
in this database since they do not have a 
protocol and therefore no data is available 
to perform analysis on.  There are however 
11 females and 17 males on omalizumab. 
This medicines is administered as an 
injectable for subcutaneous use for 
patients 12 years of age and older 
Table 1 Adaptation of differences in medicine effects between women and men6  
Medicine Advice
Aspirin
Higher dosages in women recommended for secondary prevention after a cardiovascular event due to poorer  
platelet inhibition
Atenolol Monitor blood pressure and heart rate since as less  effective in women
Digoxin Women require a lower dosage due to association with high mortality risk
Morphine Men require a higher dosage than women since the response is less in men
Paroxetine More effective in women suffering from depression 
Amitriptyline Choose alternative with improved effectiveness in women
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indicated for patients with moderate to 
severe persistent allergic periannual asthma.  
This data does not provide much information 
and since it is so limited a full picture 
related to medication consumption for 
asthma cannot be seen.
Gender differences in drugs used for 
schizophrenia use in Malta
Various studies have shown that there are 
gender differences in risk of developing 
schizophrenia. Women are more likely to be 
diagnosed as compared to men.6  Studies 
have also shown that women respond 
differently to certain classes of drugs used 
in schizophrenia, since there is an enhanced 
effect with respect to the medicines used 
in the females (Table 1). In Malta, however, 
entitlement data for March 2014  indicates 
that the number of patients on clozapine, 
which is a controlled medication due 
to potential for agranulocytosis which 
necessitates that it is used with caution, 
was found to be the same for both sexes - 90 
females and 90 males respectively. 
The use of other antipsychotics could not 
be estimated since none of theses medicines 
are regulated by a protocol. In addition, 
until 2012, most of the central nervous 
system conditions were included under the 
only listed mental health condition on the 
Schedule V Act9, that is, schizophrenia once 
again presenting a highly inaccurate picture.. 
Gender differences in drugs used  
for blood disorders and cardiovascular 
disease in Malta
Deferasirox, an iron chelator used in the 
management of thalassemia is the current 
oral preparation used in Malta. Prior to 
2011 this treatment was only available as 
an injectable, presenting challenges with 
adherence to therapy. The valid approvals in 
2014 indicate that there are 11 males and 
8 females on oral treatment.  It has been 
repeatedly reported that female patients 
with thalassemia major survive longer than 
males. This difference has been attributed to 
a lower rate of cardiac disease in females.18-21 
It has also been suggested that females have 
a better compliance with treatment than 
males and, therefore, accumulate less iron 
in crucial organs such as the heart and the 
liver. 18-21 This latter hypothesis is however 
not supported in Malta because there is no 
difference in the ferritin levels of male and 
female thalassemia patients. 
Gender differences, may also be observed 
in the treatment for cardiovascular disease.22 
Certain conditions present differently 
in males and in females. These include 
myocardial infarction, where in men, the 
predominant symptom is usually chest pain, 
women  present with chest pain, shortness 
of breath, nausea, indigestion and fatigue23.  
Gender and ethnic variables in medication 
use in these conditions are still being 
debated.22
Table 2 gives an overview of the number 
of patients on angiotensin II receptor 
blockers and statins.  Statistical analysis 
of these patients using a student t-test 
concluded that there is no statistically 
significant difference between the two gender 
groups (p>0.05).  The Pearson Correlation 
was found to be 0.97. This, once again, is not 
as expected, throwing substantial doubt on 
the quality of the data available.
Conclusion
The information presented in this paper 
highlights the limitations of the inferences 
that can be drawn from the data available. It 
is difficult to obtain information on prevalence 
of chronic diseases and even harder to obtain 
information about drug consumption. The 
latter has to be obtained through entitlement 
data, for protocol regulated drugs ,which 
as demonstrated, does not provide reliable 
information in terms of consumption.    At best 
the Schedule V entitlement data may only be 
used in conjunction with CPSU data as a loose 
indicator of total national consumption of 
medicines according to the entitled condition.  
Due to these limitations it is even more 
difficult to obtain gender specific data.
Malta requires a national drug 
consumption database. In addition an 
integrated Information Technology system 
with the appropriate focus would assist in 
providing better data which would enhance 
patient management. This would also enable 
gender specific information to be generated, 
enabling improved resource management and 
patient care.
Table 2: Drugs used for cardiovascular conditions (valid approvals as available in March 2014)
Medicine Females Males
Angiotensin II Receptor Blocker 9869 7438
Statin (simvastatin)* 6607 7227
Fluvastatin 2849 2970
Rosuvastatin 30 44
* Valid permits as they had been issued for a considerable number of years.  Item no longer requires a permit
Key points
•	 Physiological differences between sexes, affect the pharmacokinetics and the 
pharmacodynamics of drugs.
•	 Women are 50 to 75 percent more likely than men to experience an adverse drug 
reactions.
•	 In Malta data regarding medicine consumption in general or according to gender is 
exceptionally difficult to determine.
•	 Gender approach to medicines is not taken into consideration within the NHS 
•	 Differences in gender and medicine use have not resulted as being significant in Malta. 
However, this may be due to the poor quality of data available and the current local 
entitlement/prescribing system.
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